IMRX stock forecast, quote, news & analysis
Immuneering Corp is a biopharmaceutical company... Show more
Why Immuneering Corporation (IMRX) Stock Is Down -11% in the Last 30 Days
Key Takeaways
- Immuneering Corporation (IMRX) shares declined approximately 11% over the past 30 days, falling from $4.76 to $4.24 amid sustained selling pressure in the biotech sector.
- The stock had partially recovered from a steeper post-ASCO selloff in early June, climbing back above $5.50 in early July, only to give up those gains in the second half of the month.
- An analyst downgrade from Wall Street Zen — shifting from "hold" to "sell" — compounded negative sentiment around the stock in mid-July.
- Despite the near-term weakness, the broader analyst consensus remains "Moderate Buy" with an average price target of roughly $16.57, reflecting confidence in the company's late-stage pipeline.
- Over the quarter, IMRX is down roughly 19%, driven primarily by a "sell-the-news" reaction following updated Phase 2a data presented at ASCO 2026.
Immuneering Corporation (IMRX) Company Overview and Market Position
Immuneering Corporation is a clinical-stage oncology company focused on developing a new category of cancer medicines called Deep Cyclic Inhibitors. Its lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability across MAPK pathway-driven tumors, including pancreatic cancer and non-small cell lung cancer. The company leverages computational biology and proprietary platforms to identify and advance novel drug candidates. Immuneering has attracted strategic attention from major pharmaceutical players — SNY (Sanofi) made a $25 million private placement investment in September 2025, and the company has clinical supply agreements with LLY (Eli Lilly) and REGN (Regeneron) for combination studies. With a cash runway extending into 2029 and a U.S. composition-of-matter patent protecting atebimetinib into 2042, Immuneering occupies a unique position in the oncology space.
Immuneering Corporation (IMRX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, IMRX has declined approximately 11%, falling from a close of $4.76 on June 26 to an intraday price of $4.24 as of July 28. The stock initially showed resilience, rallying from its early-June trough near $3.93 to a peak of $5.53 on July 8 — a gain of roughly 40% from the low. However, that momentum reversed sharply in the second half of July, with back-to-back sessions posting declines of 7.4% on July 16 and 7.5% on July 20. The stock continued to grind lower through the final week of July.
Zooming out to the full quarter, the picture is more challenging. From a close of $5.23 on April 28 to the current level, IMRX has shed roughly 19%. The single largest driver of the quarterly decline occurred on June 1, when shares plummeted 22% in a single session following the presentation of updated Phase 2a data at the ASCO 2026 Annual Meeting — a classic "sell-the-news" event despite clinically encouraging results.
What Drove IMRX Stock Price in the Last 30 Days
The 30-day decline in IMRX reflects a convergence of several headwinds. First, the early-July recovery lost steam as profit-taking set in following the rapid bounce from June's lows. Second, Wall Street Zen downgraded the stock from "hold" to "sell" on July 20, citing valuation concerns and a mixed technical picture. The downgrade coincided with a period of broader weakness in small- and mid-cap biotech names, amplifying downward pressure on IMRX. Third, trading volumes have steadily declined through the latter half of July, suggesting waning conviction among buyers and leaving the stock vulnerable to downside moves on modest selling pressure. Absent any new company-specific catalysts in recent weeks, IMRX has drifted lower alongside sector-wide caution as investors await concrete updates on the planned Phase 3 trial launch.
What Drove IMRX Stock Performance Over the Last Quarter
The quarterly performance was dominated by the ASCO 2026 data readout in late May/early June. Immuneering presented updated overall survival data for atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, reporting a median overall survival of 17.3 months — more than double the roughly 8.5-month historical benchmark for chemotherapy alone. The data were objectively strong and reinforced the drug's potential. However, shares sold off approximately 22% on June 1 as investors who had bid up the stock ahead of the conference took profits. This dynamic overshadowed what was otherwise a constructive quarter operationally: the company had previously raised $225 million in cumulative financing, secured a Sanofi strategic investment, received a key U.S. composition-of-matter patent for atebimetinib, and outlined a clear path toward a pivotal Phase 3 trial expected to begin dosing patients in mid-2026.
Trending AI Robots
Investors seeking a data-driven edge in volatile markets like biotech may find value in Tickeron's Trending AI Robots page. Tickeron offers hundreds of AI-powered trading bots that actively trade thousands of tickers across diverse strategies, timeframes, and performance profiles. The Trending AI Robots section curates only the top-performing and most relevant bots, making it easier for traders to identify strategies that align with current market conditions. Whether you are tracking momentum, swing-trading breakouts, or looking for mean-reversion signals, these bots provide actionable, algorithm-driven insights. Exploring the page can help traders discover systematic approaches that complement their own research.
IMRX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several milestones could meaningfully influence IMRX shares. The planned initiation of the pivotal Phase 3 trial of atebimetinib plus mGnP in first-line pancreatic cancer — expected in mid-2026 — represents the single most important near-term catalyst. Updated survival data from the ongoing Phase 2a study is anticipated in the first half of 2026, possibly at a major medical meeting. Additionally, the company expects to dose the first patient in a combination trial of atebimetinib with REGN's Libtayo in non-small cell lung cancer in the second half of 2026. Macroeconomic factors, including interest-rate expectations and risk appetite for pre-revenue biotech companies, will also continue to influence sentiment. With a strong cash position extending into 2029, dilution risk appears limited in the near term, though clinical execution and regulatory feedback remain the pivotal variables for long-term value creation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
IMRX's Stochastic Oscillator is sitting in oversold zone for 11 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMRX's RSI Indicator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRX advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .
IMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 141 cases where IMRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMRX as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for IMRX turned negative on July 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .
IMRX moved below its 50-day moving average on July 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IMRX crossed bearishly below the 50-day moving average on July 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IMRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.294) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (420.906).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology